Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Peritoneal Cancer.

The Georgetown Public Hospital Corporation (GPHC) in a release yesterday announced that its medical staff performed Guyana’s first neonatal peritoneal dialysis, describing it as a groundbreaking ...

INCB-123667 is under clinical development by Incyte and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I drugs for Peritoneal Cancer have an 85% phase transition success ...

Several high-profile health systems will take the stage at JPM across Monday and Tuesday. Highlights include presentations ...

Medicine distribution halted at Kozhikode Medical College for 6 days, affecting over 500 dialysis patients. Patients face ...

IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, is pleased to announce that ...

The Philippine Health Insurance Corporation (PhilHealth) on Friday announced a significant expansion of its benefits package ...

The Philippine Health Insurance Corporation (PhilHealth) announced today in simple ceremony held in Pasig City ...

In vivo perturbations and single-cell RNA-seq reveal cell-type-specific STAT1-IFNg signaling in regulation of trained immunity in tissue-resident immune cells.